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ABSTRACT
Postoperative nausea and vomiting (PONV) is among the most important concerns of patients undergoing surgery. The 
incidence ranges  from 30% to 70%. The incidence of PONV correlates with a number of risk factors a patient possesses. 
Patient-related risk factors in adults are: female gender, history of PONV, duration of surgery > 60 min, nonsmoking status, 
history of motion sickness, and postoperative use of opioids. Risk factors in children are: duration of surgery  30 minutes, 
age  3 years, strabismus surgery, and a history of PONV in the patient, parent or sibling. Treatment of PONV includes 
various classes of medications and none of them is entirely effective. If it is necessary to use combination therapy, then 
medicines with different sites of activity should be used. Promethazine is a phenothiazine derivate available as a medicine 
since its introduction in 1946. In this article, a search was performed to identify all published papers and reports evaluating 
the effectiveness of promethazine for the management of postoperative nausea and vomiting in adults and children. The 
results of this review support the finding that promethazine is not recommended as a first-line agent  in the treatment of 
PONV, but can be considered for use as a rescue antiemetic.   
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Introduction
Postoperative nausea and vomiting 
(PONV), together with  pain, is among 
the most important concerns of patients 
undergoing surgery. Nausea, vomiting 
and retching can occur with all types of 
anesthesia (general, regional or local). 
(1) The incidence ranges  from 30% to 
50%, with numbers reported as high 
as 70% in higher-risk patients. (2) Con-
sequences of PONV are numerous and 
include rupture of stitches, bleeding, 
electrolyte imbalances, dehydration, 
and aspiration of gastric contents. (3, 
4) Patients who experience PONV also 
require additional health care. All of this 
may delay  discharge from the post-
anesthesia care unit (PACU) or require 
additional medical interventions, resul-
ting in increased health care costs. 
This article will review the therapeu-
tic efficacy of promethazine in the tre-




Current strategies for the prevention of 
PONV include: (a) proactive risk asse-
ssment, (b) avoiding PONV “triggers”, 
and (c) administration of prophylactic 
antiemetic medications. (1) 
Apfel et al. created a risk assessment 
scoring system and included four pati-
ent-related risk factors in it: female 
gender, nonsmoking status, history of 
PONV or motion sickness, and posto-
perative use of opioids. (5) Koivuranta 
et al. created a similar scoring system, 
but with five factors: female gender, 
history of PONV, duration of surgery > 
60 min, nonsmoking status, and history 
of motion sickness. (6) The incidence of 
PONV correlates with the number of risk 
factors a patient possesses. A pediatric 
scoring system has been designed by 
Eberhart et al. (7) Risk factors associa-
ted with increased frequency of PONV 
in children are: duration of surgery  
30 minutes, age  3 years, strabismus 
surgery, and a history of PONV in the 
patient, parent or sibling. 
Consensus panel guidelines, develo-
ped under the auspices of the Society 
of Ambulatory Anesthesia, recommen-
ded the prophylactic use of antiemetic 
therapy only for patients who are at 
moderate to high risk for developing 
PONV.  
A modified and simplified treatment 
algorithm for the management of PONV 
is shown in figure 1. 
As shown in figure 1, treatment of PONV 
includes various classes of medicati-
ons. None of the available antiemetics 
is entirely effective. If it is necessary to 
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use combination therapy, then  medici-
nes with different sites of activity sho-
uld be used to optimize efficacy. (8) 
All prophylaxis in children at moderate 
or high risk for postoperative vomiting 
should include combination therapy 
using a serotonin (5-HT3) antagonist 
and a second medicine. (8)
Promethazine offers the advantage of 
low cost, slow-intramuscular absorpti-
on, and a long elimination half-life (9), 
making it potentially attractive for use in 
outpatient surgery. (9, 10)
Promethazine in treatment 
of PONV
Promethazine is a phenothiazine deri-
vate available as a medicine since 
its introduction in 1946. It acts as a 
histamine H1-receptor antagonist with 
moderate muscarinic and dopamine 
(D2) receptor blocking activities. (11) 
Promethazine is available worldwide, 
in some countries as over the counter 
medicine, and in some only by pres-
cription. It is available in the form  of an 
injection, oral liquid and tablet. Indica-
tions for use are: treatment of allergies, 
adjunct to anesthesia, motion sickness, 
nausea and vomiting from any cause, 
adjunct to management of post-opera-
tive pain, general sedation, and obste-
tric sedation. It is contraindicated  in 
patients with known hypersensitivity 
to promethazine (cross reactivity with 
other phenothiazines may also occur), 
in patients with severe toxic central 
nervous system (CNS) depression or 
coma, and in children < 2 years of age. 
(12) Promethazine should be used with 
extreme caution in children, due to the 
potentially severe risk of respiratory 
depression. Sudden deaths in children 
have been associated with excessively 
high doses of promethazine. Therefore, 
the lowest effective doses are recom-
mended  in children and concomitant 
use of other medications having res-
piratory depressant effects should be 
avoided. 
Promethazine should not be given 
subcutaneously or intra-arterially due to 
severe local reactions including necro-
sis. Intravenous (I.V.) administration 
may also cause serious tissue reactions 
and it should be used only in emergen-
cy situations or when intramuscular or 
oral administration is contraindicated. 
Veins should be large and patent. Pro-
methazine should be used with caution 
in patients with cardiovascular disea-
se, narrow-angle glaucoma, prostatic 
hypertrophy, bone marrow depression, 
impaired liver function, asthma, pep-
tic ulcer disease, sleep apnea, and 
hypertensive crisis. Promethazine may 
lower the seizure threshold so it should 
be used with caution in patients with 
seizure disorders or if they are recei-
ving other medications which may also 
lower the seizure threshold. Adverse 
effects of promethazine are numerous 
and they include cardiovascular symp-
toms (tachycardia, bradycardia, hypo-
tension, hypertension), CNS symp-
toms (sedation, excitation, extrapyra-
midal reactions, dystonia, neuroleptic 
malignant syndrome, hallucinations, 
insomnia), dermatologic symptoms 
(photosensitivity, rash), gastrointesti-
nal symptoms (xerostomia, abdominal 
pain, diarrhea), hematologic symptoms 
(thrombocytopenia, agranulocytosis), 
and other such as cholestatic jaundice, 
hepatitis, thrombophlebitis, blurred visi-
on, and tinnitus. (12)
When administered for the treatment 
of nausea and vomiting, promethazine 
dosage regimen in adults should be  25 
mg orally at night, increased to 50–75 
mg at night or 25 mg 2–3 times daily 
if necessary (maximum, 100 mg in 24 
hours), or by deep intramuscular injec-
tion or by slow intravenous injection 
12.5–25 mg, repeated at intervals of not 
less than 4 hours (usual maximum, 100 
mg in 24 hours). (13)
The review of promethazine 
effectiveness in treatment 
of PONV
Medline, Cochrane Database of Sys-
tematic Reviews, and Cochrane Cen-
tral Register of Controlled Trials (1970 
– June 2010) were searched to identify 
all published papers and reports evalu-
ating the effectiveness of promethazine 
for the management of postoperative 
nausea and vomiting in adults and chil-
dren. Search terms were promethazine, 
and postoperative nausea and vomiting. 
Studies in languages other than English 
were excluded. Titles and  abstracts of 
retrieved papers were reviewed. Studies 
were included  if they were systematic 
reviews or randomized controlled trials 
(RCTs). Non-randomized clinical trials 
were also included if the data published 
in them was considered relevant for this 
review. The reference  lists of included 
studies were hand searched to iden-
tify any additional studies. The studies 
in which promethazine was used as 
part of a combination of medicines (for 
example, lytic cocktails) were excluded. 
Different medicines, doses, and regi-
mens have been used in these studies 
and the findings cannot be used to 
conclude  which agent is most effective 
for preventing PONV.
After analysis of retrieved papers, 19 
relevant clinical trials and 4 systematic 
reviews were identified evaluating the 
effectiveness of promethazine for the 
management of PONV.  Data relevant 
for evaluation of promethazine effec-
tiveness was extracted and tabulated 
(table 1, table 2). 
The majority of 19 clinical trials (12/19; 
63,2%) were double-blind RCTs, 3 were 
RCTs, and 4 articles presented nonran-
Figure 1. Treatment algorithm modifi-
ed from Gan et al. (8)
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Table 1. Clinical trials evaluating the effectiveness of promethazine for the management of PONV.
No. Article; Study Type; Study Design Conclusion
01.
Conner (1977) (14)
Double-blind RCT; Adults aged 18 – 70 years (N = 270)
One hour before surgery, patients received morphine 5 mg or 
10 mg alone or in combination with promethazine 6.25, 12.5, 
or 25 mg. Promethazine 25 mg alone also was studied.
The use of promethazine had no effect on incidence of nau-
sea. Also, it was reported that there was no statistically signifi-
cant difference between the various doses of promethazine.
02.
Dodson (1978) (15)
Double-blind RCT; Women aged 16 – 70 years (N = 124)
As a premedication, 2-3 hours before surgery: 1. lorazepam 
2.5 mg p.o.; 2. promethazine 50 mg p.o.
Vomiting during anesthesia, or during the 1st hour after surgery 
occurred in 8 patients, of whom 7 received lorazepam. There 
was no difference between the groups in respect to late PONV.
03.
Vella (1985) (16)
Double-blind RCT; Women in labour (N = 477).
Patients received pethidine (100-150 mg) i.m. along with 
either: 1. isotonic saline (2 ml, Control group); 2. prometh-
azine 25 mg; 3. metoclopramide 10 mg 
Both metoclopramide and promethazine prevented the 
increase in nausea and vomiting associated with pethidine 
administration, with promethazine having a more sustained 
effect - by 4 hours promethazine produced a significant reduc-
tion in nausea from the level before pethidine administration.
04.
Blanc (1991) (10)
Double-blind RCT; Children aged 2 – 10 years (N = 100; 47 M 
+ 53 F)
Patients received: 1. droperidol 0.075 mg/kg i.v. + placebo 
i.m.; 2. promethazine 0.5 mg/kg i.v. + promethazine 0.5 mg/
kg i.m. (max. 25 mg)
The incidence of vomiting pre-discharge in groups 1 and 2 
was not significantly different. The incidence of vomiting post-
discharge and overall was significantly higher with droperidol 
than with promethazine. 
Promethazine pretreatment reduced the incidence of postop-
erative vomiting in unpremedicated children.
05.
Silverman (1992) (17)
RCT; Women aged 18 – 60 years (N = 30)
In patient care unit, patients were assigned to 
receive patient-controlled analgesia: 1. morphine; 2. 
morphine+promethazine 0,625 mg with each morphine 
dose (average of 17,6 mg over 24-h period)
Visual analogue scale (VAS) scores for nausea were not sig-
nificantly different between the two groups.  
The addition of promethazine to morphine was associated 




RCT; Women aged between 22.4 ± 2.5 and 25.0 ± 4.88 years 
(N = 32)
Patients received pentazocine 0.6 mg/kg i.v. 5 minutes before 
induction of anesthesia along with either: 1. isotonic saline 
(Control group); 2. promethazine 0.5 mg/kg; 3. metoclopra-
mide 0.2 mg/kg  
Promethazine and metoclopramide in the doses used in this 
study are ineffective for antiemetic prophylaxis.
07.
Tarkkila (1995) (19)
Double- blind RCT; Adults aged 50 – 83 years (N = 60)
For premedication the patients received: 1. oral diazepam 
5-15 mg + placebo patch; 2. oral promethazine 10 mg + 
placebo patch: 3. oral promethazine 10 mg + transdermal 
scopolamine patch 1.5 mg
The combination of oral promethazine and transdermal 
scopolamine was most effective in reducing PONV and also 
reduced the need for postoperative pain treatment.
08.
Rodola (1995) (20)
Double- blind RCT; Adults aged 18 – 40 years (N = 120; 58 M 
+ 62 F)
Premedication before surgery: 1. no treatment = Control group; 
2. atropine 0,01 mg/kg i.m. + diazepam 0.2 mg/kg p.o.; 3. atro-
pine 0,01 mg/kg i.m. + promethazine 1 mg/kg i.m.
The combination of promethazine and atropine was very effec-
tive in reducing occurrence of PONV.
Promethazine is suggested as an effective and inexpensive 
medication to prevent PONV in orthopedic surgery.
09.
Khalil (1999) (21)
Double- blind RCT; Adults aged 13 -72 years (N = 87; 46 M 
+ 41 F).
At induction of anesthesia, patients received: 1. ondansetron 
4 mg; 2. promethazine 25 mg; 3. promethazine 12.5 mg + 
ondansetron 2 mg; 4. placebo
Over the 24-h period, the incidence of nausea was significantly 
reduced in promethazine and combination group compared 
with placebo group.  Incidence of vomiting was significantly 
reduced in combination group compared with promethazine, 
ondansetron and placebo group. 
Incidence of combined nausea and vomiting was reduced in 
promethazine and combination group compared with placebo 
group. 
Combination of ondansetron and promethazine and promet-
hazine alone are effective and inexpensive choices. 
10.
Parlow (1999) (22)
Double-blind RCT; Women aged 35 ± 9 years (N = 95)
Patients received droperidol 0.5 mg i.v. intraoperatively, and 
prior to transfer from post-anesthetic recovery room: 1. pro-
methazine 0.6 mg/kg i.m.; 2. placebo
The incidence of nausea, vomiting, and rescue antiemetic use 
in the recovery room was similar between the groups. Promet-
hazine had no effect on postdischarge nausea scores, vomit-
ing, or rescue antiemetic requirements.
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No. Article; Study Type; Study Design Conclusion
11.
Kreisler (2000) (23)
Double-blind RCT; Adults aged between 46.7 ± 15.7 and 50.0 
± 15.3 years (N = 150;59 M+91 F)
Before emergence from general anesthesia, patients received 
PONV prophylaxis: droperidol 0.625 mg i.v. or placebo. If 
PONV occurred in the postanesthesia care unit, patients 
received rescue antiemetic (N = 31): 1. droperidol 0.625 i.v.; 
2. ondansetron 4 mg i.v.; 3. promethazine 12.5 mg i.v.
Significantly more people in placebo group experienced PONV 
than in droperidol prophylaxis group. Because of the small 
sample size, the authors were unable to show statistically sig-
nificant difference in efficacy among different medicines.
12.
Ikechebelu (2003) (24)
Retrospective study; Women aged 18 – 40 years (N = 295)
Premedication: 1. atropine 0.6 mg; 2. atropine 0.6 mg + 
diazepam 10 mg; 3. atropine 0.6 mg + promethazine 50 mg
Promethazine significantly reduced nausea and vomiting. Pre-




Double-blind RCT; Women aged between 44.0 ± 10.2 and 
47.0 ± 5.2 years (N = 90)
1. Pre-group - received promethazine 0.1 mg/kg infusion 
before anesthesia induction
2. Post-group - received promethazine 0.1 mg/kg infusion at 
the end of surgery
3. Control group - received normal saline
There were significant differences regarding nausea, vomit-
ing, and patients who asked for antiemetic at the first 0-6 h 
and 0-24 h after surgery between group 3 and groups 1 and 
2. Administration of promethazine pre- or post- operatively 
reduced PONV and the number of patients asking for rescue 




Prospective study (nonrandomized); Adults aged 27 – 81 
years (N = 87)
1. promethazine 6.25 mg or 12.5 mg i.v.; 2. ondansetron 4 mg i.v.
There were no significant differences between the groups 
concerning relieve of nausea and vomiting at 1 and 3 hours. In 
patients requiring treatment for nausea and/or vomiting from 
any cause except chemotherapy or pregnancy, promethazine 
was as effective as ondansetron.
15.
Habib (2005) (27)
Retrospective review (not randomized); Adults aged 18 – 65 
years (N = 431)
Rescue antiemetic in PACU: 1. ondansetron 4 mg; 2. droperi-
dol 0.625 to 1.25 mg; 3. metoclopramide 10 mg; 4. prometh-
azine 6.25 to 25 mg; 5. dimenhydrinate 25 to 50 mg.
In the original double-blind RCT, patients (N = 2061) received 
PONV prophylaxis before the induction of anesthesia: ondanse-
tron 4 mg, droperidol 0.625 or 1.25 mg, or placebo. (28)
In patients who failed prophylaxis with ondansetron, the com-
plete response rate (no nausea, no emesis, no need for further 
rescue) after rescue with promethazine was significantly higher 
compared with a second dose of ondansetron. In patients who 
failed prophylaxis with droperidol, the complete response rate 
was significantly higher after rescue with promethazine and 
dimenhydrinate compared with a second dose of droperidol. 
An antiemetic acting at a receptor different from the site of 
action of the medicine used for PONV prophylaxis should be 
considered for the treatment of established PONV.
16.
Nale (2007) (29)
Double-blind RCT; Adults aged 16 – 80 years (N = 120).
Oral premedication 1 hour prior surgery and subsequent at 8 
hour intervals for total 24 hours:
1. shaving of fresh ginger 250 mg; 2. metoclopramide 10 
mg; 3. prochlorperazine 5 mg; 4. promethazine 20 mg; 5. 
ondansetron 4 mg; 6. placebo
The frequency and quantity of PONV was significantly lower in 
the  ginger group than in the control group.
The incidence of nausea was considerably less with promet-
hazine than in the control group.  
17.
Habib (2007) (30)
Retrospective review (not randomized); Adults aged > 18 
years
Patients  (N = 18209) initially received PONV prophylaxis 
with ondansetron 4 mg. Rescue antiemetic administered in 
PACU within 4 hours after PONV prophylaxis (N = 3814): 1. 
ondansetron 4 mg; 2. promethazine 6,25; 12,5 or 25 mg
In patients with established PONV who failed ondansetron 
prophylaxis and needed rescue antiemetic treatment, the 
response rate (no nausea, no emesis, no need for further 
rescue) was significantly higher after promethazine than after 
repeat dose of ondansetron.
There was no difference in efficacy between 6.25 mg and 
higher doses of promethazine for the treatment of established 
PONV in those patients.
18.
Pellegrini (2009) (31)
RCT; Adults aged between 33.98 ± 10.9 and 37.09 ± 11.0 
years (N = 85)
Patients received PONV prophylaxis with ondansetron 4 mg. 
Rescue (PONV) treatment with: 1. inhaled 70% isopropyl 
alcohol (IPA); 2. promethazine 12,5 to 25 mg i.v.
IPA is as effective in treating PONV as promethazine in patients 
who have been identified as high risk for PONV.
19.
Gan (2009) (32)
Double-blind RCT; Women aged between 32.8 ± 7.2 and 34.3 
± 8.3 years (N = 138)
15 min before the end of surgery i.v. and than 12 h after sur-
gery for five oral doses, patients received:
1. granisetron 0.1 mg i.v. (1 mg oral) ; 2. promethazine 6.25 
mg i.v. (12.5 mg oral); 3. granisetron + promethazine (com-
bination, same doses as above)
Patients in the combination group had a significantly higher 
cumulative total response rate (no vomiting/retching, no more 
than mild nausea, no use of rescue antiemetic) compared 
with promethazine group. The maximum nausea scores were 
significantly lower in the combination group than in the pro-
methazine group. There was no difference between groups in 
satisfaction with PONV management.
Combination of granisetron and promethazine is more effective 
in reducing PONV and PDNV than promethazine monotherapy.
F, females; M, males; N, number; PACU, post-anesthesia care unit; PONV, postoperative nausea and vomiting; RCT, randomized controlled trials.
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Table 2. Systematic reviews evaluating the effectiveness of promethazine for the management of postoperative nausea 
and vomiting.
No. Article; Methodology
Remarks / Results concerning pro-
methazine role
Conclusions; Comment
01. Tramer (1999) (33)
MEDLINE (1966 – Apr 1998), EMBASE 
(1980 – Apr 1998), and Cochrane library 
search was conducted. Included one 
study with promethazine (17)
The addition of promethazine to mor-
phine was associated with a significant 
decrease in the symptom-therapy score 
for nausea.
Promethazine showed promising results 
but the number of patients is limited and 
the recommendations cannot be based 
on the available evidences.
02. Fujii (2005) (34)
MEDLINE and EMBASE search (Jan 
1990 – Oct 2003) was conducted.
Included two studies with promethazine 
(21), (22)
Over the 24-h period, the incidence 
of PONV was significantly reduced in 
promethazine group and combination 
group of promethazine and ondanse-
tron compared with placebo group and 
ondansetron group. (21)
There was no difference between the 
placebo and promethazine groups in 
the worst level of nausea reported, the 
incidence of nausea of any severity, 
moderate to severe nausea, vomiting, or 
the need for rescue antiemetics follow-
ing discharge. (22) 
Among traditional antiemetics (e.g., 
anticholinergics, antihistamines, phe-
nothiazines, butyrophenones, and 
benzamide), dimenhydrinate and 
perphenazine are highly efficacious for  
prophylaxis against PONV following lap-
aroscopic cholecystectomy.
03. Carlisle (2006) (35)
Cochrane systematic review
The Cochrane Central Register of Con-
trolled Trials (Jan 1966 - May 2004), 
EMBASE (Jan 1985 - May 2004), 
CINAHL (1982 - May 2004), ISI WOS (to 
May 2004), Lilac, and Ingenta searches 
were conducted.
Included 7 clinical trials from Table 1 
evaluating the effectiveness of promet-
hazine: (21), (22), (10), (19), (15), (20), 
(18)  
Compared to placebo, the risk for PONV 
is decreased by promethazine, but 
there was no evidence that the risk of 
postoperative vomiting is changed by 
promethazine.
Compared to no treatment, there was no 
evidence that promethazine changes the 
risk of postoperative nausea, or the risk 
of postoperative vomiting.
Eight medicines (droperidol, metoc-
lopramide, ondansetron, tropisetron, 
dolasetron, dexamethasone, cyclizine 
and granisetron) were identified that reli-
ably prevented nausea or vomiting after 
surgery. 
There was no reliable evidence that one 
medicine was better than another.
04. Fujii (2008) (36)
MEDLINE and EMBASE searches from 
Jan 1990 to Dec 2007 were conducted.
Included one study with promethazine 
(21)
Over the 24-h period, the incidence 
of PONV was significantly reduced in 
promethazine group and combination 
group of promethazine and ondansetron 
compared with placebo group. 
There was no difference between pla-
cebo and ondansetron groups. 
Combination of antiemetic therapy 
with an antiserotonin (ondansetron, 
granisetron) plus traditional antiemetics 
(promethazine, droperidol) or dexam-
ethasone is highly effective for the pro-
phylaxis against PONV.
domized prospective or retrospective 
studies. The quality of data collection 
was operator-dependent and in some 
aspects, like the evaluation of seve-
rity of nausea, may be inaccurate or 
underreported. Objective evaluation 
of severity of nausea is very difficult 
and “there may be as many scales for 
assessing nausea/vomiting as there 
are investigative groups studying the 
phenomenon”. (37) Four clinical trials 
used validated visual analogue (VAS) 
or verbal rating (VRS) scales to assess 
nausea with “0” representing no nausea 
and “10” representing worst possible 
nausea, in seven clinical trials the seve-
rity was not assessed or it was unclear 
how the assessment was done, and 
the other eight reported using a sco-
ring system which was  not validated, 
and was  not reported again in other 
articles. Additional limitations are the 
low or limited number of patients ava-
ilable for analysis, the recruitment of 
only women, and the non-existence of 
placebo groups in some studies. The 
limitation of some nonrandomized 
studies was the choice of antieme-
tic medicines, which was left to  the 
discretion of the attending anesthesi-
ologist. However, those clinical trials 
evaluated the effectiveness of pro-
methazine in 6486 patients of which 
6299 were adults aged 16 or more, 
and 100 were children. One clinical 
trial included 87 patients aged 13 – 72 
years, but we were unable to identify 
the exact number of participants that 
were under or over 16 years from the 
published data. (21)  Promethazine 
was used in different dosages and 
administered using  different routes 
of administration (oral, intramuscular, 
intravenous, combined intramuscular 
+ intravenous) across the studies. 
The use of different dosages may have 
led to different effects.  The doses 
of promethazine were determined in 
PONV, postoperative nausea and vomiting.
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three ways:in 12 studies, the dose of 
promethazine was fixed and ranged 
from 6,25 mg to 50 mg; in 5 studies, 
the dose of promethazine was calcu-
lated according to the patient’s body 
weight (each of these studies used 
different dosing regimes, with doses 
ranging from 0,1 mg/kg to 1 mg/kg) 
and in one study, promethazine was 
added to morphine as part of a pati-
ent-controlled analgesia regimen and 
the patient was administered on ave-
rage 17,6 mg of promethazine over a 
24-h period. 
Due to the heterogeneity of the retrie-
ved clinical trials, it was not possible 
to pool the data in a meta-analysis as 
no common or unique outcome could 
be determined.  In order to analyze the 
effect of promethazine as precisely as 
possible, the outcomes of retrieved 
clinical trials presented in Table 1 are 
reported by the intervention used. Six 
different groups were identified:
1) Promethazine vs. placebo
In seven clinical trials (16, 18, 20-22, 24, 
25), promethazine was compared to 
placebo. In 5 of them women only par-
ticipated (N = 989; aged 18 – 55 years), 
one trial was with adults (N = 120) aged 
18 – 40 years, and one trial included 87 
patients aged 13 – 72 years. Promet-
hazine was found effective in reducing 
the occurrence of PONV in 5 articles, 
while 2 studies found it  ineffective for 
antiemetic prophylaxis.
2) Promethazine vs. another antiemetic 
medicine  
In three clinical trials (13, 26, 29), pro-
methazine was compared to another 
antiemetic medicine. One study with 
children (N = 100), aged 2 – 10 years, 
reported that promethazine reduced 
the incidence of postoperative vomiting 
when compared to droperidol, and the 
other with adults (N = 87) aged 27 – 81 
years, found promethazine as effec-
tive as ondansetron. The third study, 
with patients aged 16 – 80 years (N = 
120), found that shavings of fresh gin-
ger decreased the incidence of PONV 
significantly when compared to place-
bo. The same study also evaluated the 
effect of promethazine and found that 
the incidence of nausea was conside-
rably less with promethazine than in the 
control group.
3) Promethazine + another antiemetic 
vs. placebo or the same antiemetic 
alone  
In three clinical trials (19, 21, 32), com-
bination of promethazine with another 
antiemetic was compared to placebo 
or to those same antiemetics admini-
stered alone. The study with 87 pati-
ents, aged 13 – 72 years, reported that 
a combination of promethazine with 
ondansetron reduced the incidence 
of nausea, vomiting and combination 
of nausea and vomiting when compa-
red with placebo. The same study also 
reported the combination of promet-
hazine and ondansetron to be more 
effective in reducing the incidence of 
vomiting and combined nausea and 
vomiting than promethazine or ondan-
setron alone. The second study with 
women (N = 138), aged 32.8 ± 7.2 and 
34.3 ± 8.3 years, reported the combi-
nation of granisetron and promethazine 
to be more effective in reducing PONV 
than promethazine monotherapy. The 
third study, with adults (N = 60) aged 
50 – 83 years, also reported a com-
bination of medicines to be the most 
effective. In this study, oral prometha-
zine was combined with a transdermal 
scopolamine patch, and it was found 
that this combination is more effective 
in reducing incidence of PONV than 
promethazine monotherapy.
4) Promethazine in combination with 
morphine
In two clinical trials (14, 17), the effect of 
promethazine and morphine combina-
tion on incidence of nausea was tested. 
Both studies, one with adults (N = 270) 
aged 18 – 70 years and the other with 
women (N = 30) aged 18 – 60 years 
found that the use of promethazine had 
no effect on the incidence of nausea. 
However, the later study reported that 
the use of promethazine, as an adjun-
ct to morphine, was associated with 
a decrease in the symptom-therapy 
score for nausea.
5) Promethazine as a rescue antiemetic 
(2nd line treatment) vs. other antiemetics 
In four clinical trials (23, 27, 30, 31), 
promethazine was used as a rescue 
antiemetic and was compared to other 
antiemetics. Adults (N = 4361) partici-
pated in these trials. In two studies (N 
= 116) the difference between promet-
hazine and other used medicine was 
not revealed. Other two studies (N = 
4245) found promethazine to be more 
efficient in reducing PONV then the 
repeated dose of the same antiemetic 
used for prophylaxis. 
6) Promethazine vs. lorazepam
One clinical trial (15), with women (N 
= 124) aged 16 – 70 years, compared 
promethazine to the sedative loraze-
pam. The primary outcome of this trial 
was  their effect as premedicants. How-
ever, no difference among them was 
found in respect to  late PONV.
Four systematic reviews published 
between 1999 and 2008 were identi-
fied. Two systematic reviews (33, 36) 
included only one clinical trial evalu-
ating the efficacy of promethazine in 
management of PONV. In one of them, 
it is stated that promethazine showed 
promising results in preventing nausea 
but due to limited number of patients 
a conclusion could not be  made. 
The second review recommended a 
combination of an antiserotonin plus 
traditional antiemetics (this included 
promethazine) as highly effective for 
prophylaxis against PONV. The third 
review (34) included two clinical trials 
with promethazine. Among the conclu-
sions in  this review promethazine was 
not explicitly stated. The review which 
included the most clinical trials evaluat-
ing the effectiveness of promethazine 
was a Cochrane systematic review.
(35) The objective of that review was to 
assess the prevention of postoperative 
nausea and vomiting by different medi-
cines and to compare their efficacies. In 
order to achieve that, 737 randomized 
controlled trials involving 103 237 peo-
ple that compared a medicine with pla-
cebo or another medicine were includ-
ed. Out of that, 7 clinical trials involving 
618 people evaluated the effectiveness 
of promethazine. It was found that eight 
medicines reliably prevented nausea 
or vomiting after surgery: droperidol, 
metoclopramide, ondansetron, tro-
pisetron, dolasetron, dexamethasone, 
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cyclizine and granisetron. Those medi-
cines prevented nausea or vomiting in 
three or four people out of every 10 who 
would have vomited or felt nauseated 
with a placebo. The authors did not find 
reliable evidence that one medicine 
was better than another. Side effects 
were mild. In regard to  promethazine, 
there was no evidence that the risk of 
postoperative vomiting was affected 
by promethazine. Also, compared to 
no treatment, there was no evidence 
that promethazine changed the risk 
of postoperative nausea or the risk of 
postoperative vomiting.
Conclusions
It is evident from tables 1 and 2 that 
despite its widespread use, little data 
evaluating the therapeutic efficacy of 
promethazine is available. There are 
more articles evaluating efficacy of other 
antiemetics, but evaluation of these 
treatments was beyond the scope of 
this review.  
Current guidelines do not recommend 
the use of promethazine and meto-
clopramide in the treatment of PONV, 
nor as a part of pharmagologic com-
bination for adults and children, nor 
as a single agent  in children. (8) A 
recent Cochrane Database Systematic 
Review found that, compared to pla-
cebo, the risk for PONV is decreased 
by promethazine, but there was no 
evidence that the risk of postoperative 
vomiting is changed by promethazine. 
Also, compared to no treatment, there 
was no evidence that promethazine 
changes the risk of postoperative vom-
iting and postoperative nausea.(35) 
The results of this review support the 
finding that promethazine is not recom-
mended as a first-line medicine in the 
treatment of PONV, but can be consid-
ered for use as a rescue antiemetic.   
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